Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials
Authors' conclusion
Obicetrapib lowered LDL-C, apoB and Lp(a). The absolute reduction in Lp(a) with obicetrapib was similar in patients with mildly elevated Lp(a) levels, who are unlikely to qualify for administration of RNA-targeted Lp(a) lowering agents.
Study context
- Population
- Patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) at high CV risk
- Participants
- 2,356 patients
- Comparison
- Obicetrapib 10 mg daily vs placebo
- Outcome
- Change in Lp(a) levels
- Follow-up
- 12 weeks
Methodological detailsplacebo-controlled
- Placebo-controlled
Pooled result
As reported in the abstract
Lp(a), placebo-adjusted reduction
Placebo-adjusted reduction
37.3 %
Obicetrapib
Placebo-adjusted reduction
14.9 nmol/L
Obicetrapib
Further pooled results
| Outcome | Estimate |
|---|---|
| LDL-C, placebo-adjusted reductionObicetrapib vs Placebo | placebo-adjusted reduction 37.0 % |
| LDL-C, placebo-adjusted reductionObicetrapib vs Placebo | placebo-adjusted reduction 35 mg/dL |
| apoB, placebo-adjusted reductionObicetrapib vs Placebo | placebo-adjusted reduction 21.3 % |
| apoB, placebo-adjusted reductionObicetrapib vs Placebo | placebo-adjusted reduction 20 mg/dL |
| Lp(a), baseline Lp(a) ≥50-<150 nmol/L (subgroup)Obicetrapib vs Placebo | placebo-adjusted reduction 43.3 % |
| Lp(a), baseline Lp(a) ≥50-<150 nmol/L (subgroup)Obicetrapib vs Placebo | placebo-adjusted reduction 36.3 nmol/L |
Lp(a), baseline Lp(a) ≥150 nmol/L vs ≥50-<150 nmol/L (subgroups)
- Lower percentage reduction with baseline ≥150 nmol/L; absolute reduction similar in both
- −32.3 vs −36.3 nmol/L
Original publication
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. Eur Heart J. Published 25 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →